Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.

Date publication

novembre 2020

Journal

EClinicalMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr COUDERT Bruno , Pr PETIT Thierry

Tous les auteurs :
Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Du FL, Dupré PF, Bachelot T, Gabelle P, Chauvet MP, Coeffic D, Barbe C, Prevost JB, Paintaud G, Thibault G, Ferhat A, Dupin J, Berriolo-Riedinger A, Arnould L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33205032

Résumé

The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes.

Mots clés

Bevacizumab, Early pet assessment, Her-2 positive breast cancer, Long-term follow-up, Neoadjuvant, Positron emission tomography, pathological complete response, Δsuvmax

Référence

EClinicalMedicine. 2020 Nov;28:100566